Biotech Values

[DewDiligence]

FDA approves PFE’s Xeljanz (f/k/a tofacitinib) for second-line RA:

http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm327152.htm

The U.S. Food and Drug Administration today approved Xeljanz (tofacitinib) to treat adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to, or who are intolerant of, methotrexate.

This is the broad second-line label that PFE has been hoping for.